Trethera has secured a $2.7 million NIH Small Business Innovation Research grant to evaluate its first-in-class DCK inhibitor, TRE-515, in combination with approved KRAS inhibitors for non-small cell lung cancer. The award funds preclinical studies in NSCLC mouse models designed to inform future clinical trials, targeting a well-known problem in KRAS-driven disease: only about 40% of patients respond to KRAS G12C monotherapy, and those responses often wane within 8 to 10 months. The company’s program builds on prior external validation, including FDA Fast Track designation for TRE-515 in prostate cancer, and positions Trethera to move a differentiated combination strategy toward the clinic.
The strategic question is whether metabolic rewiring is the missing piece in KRAS therapy. By inhibiting deoxycytidine kinase and the nucleoside salvage pathway, TRE-515 aims to cut off a key route cancer cells use to repair DNA and persist under KRAS blockade. If the biology translates, the combination could deepen responses and extend durability without compounding toxicity, an area where several KRAS-based combinations have struggled. This is not just another add-on; it targets a distinct tumor survival axis that has been harder to drug and could complement signaling inhibitors and immunotherapy.
For patients, the promise is straightforward: more people benefiting from KRAS-targeted treatment for longer, particularly the majority who do not respond or rapidly relapse on monotherapy. For HCPs, the clinical value will hinge on biomarker-guided selection and operational simplicity, including whether DCK activity can be visualized or tracked to identify likely responders. Payers will focus on incremental value over cost stacking. Any combination must show clear gains in progression-free survival, duration of response, and quality-of-life measures to earn formulary traction in an already crowded and expensive lung cancer armamentarium.
The competitive context is shifting toward rational combinations that tackle resistance biology head-on. While SHP2 and SOS1 inhibitors, chemotherapy backbones, and immunotherapy pairings dominate the KRAS combo landscape, a salvage-pathway approach broadens the field to tumor metabolism, where clinical validation has been sporadic but potentially powerful. If Trethera can pair a mechanistic biomarker, such as DCK imaging or circulating markers of nucleotide salvage, with clinical outcomes, it may establish a more straightforward regulatory and reimbursement path than empirical combinations. The non-dilutive financing also reflects a broader biotech playbook: stretching runway to reach a partnership-ready data signal as large pharma and mid-caps scout for KRAS-extending assets.
The near-term watchouts are concrete. Can preclinical data demonstrate synergy without exacerbating liver or hematologic toxicity that could complicate KRAS regimens? Will an early-phase Ib/II design enrich for biomarker-positive patients and provide a quick readout on duration metrics that matter to payers and guideline bodies? With KRAS remaining a marquee target yet still hampered by resistance, the next wave of winners will be those that marry strong translational biology with clean clinical execution. If metabolic targeting proves its worth, it could reset expectations for KRAS combinations—and prompt a new round of BD interest around precision metabolism in oncology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
